Diabetes Mellitus

Diabetic Nephropathies

Fenofibrate 100 mg or 300 mg (according to CrCl)

Fenofibrate

Singapore General Hospital

Effects of Fenofibrate Therapy in Diabetic Nephropathy

Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy

Percentage change in serum concentration of palmitoylcarnitine following 30 days of fenofibrate treatment compared to baseline

Percentage change in serum concentration of acetylcarnitine following 30 days of fenofibrate treatment compared to baseline

Percentage change in serum concentration of leucine following 30 days of fenofibrate treatment compared with baseline

Percentage change in serum concentration of isoleucine following 30 days of fenofibrate treatment compared with baseline

Percentage change in serum concentration of valine following 30 days of fenofibrate treatment compared with baseline

Absolute change in serum triglyceride (mmol/L) concentration following 30 days of fenofibrate treatment with baseline

Change in rate of fat oxidation (g/min) following 30 days of fenofibrate treatment

Change in ETDRS scale following 30 days of fenofibrate treatment

National Medical Research Council (NMRC), Singapore

In this single-centre, open label study, 300 adults with DN will be recruited over 3 years. Following screening and baseline metabolic evaluations, eligible subjects will be treated with fenofibrate for 30-days and re-assessed.

Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects will be be discontinued from the study.

Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site subjects

Subjects will have the TEWL reading completed at the wound site and a control site (anatomically matched site on the patients contralateral side) at the second study visit. If the wound site reading is less than 3 times the value of the control site

Chronic Wound

Burn Wound

Diabetic Foot Ulcers

Pressure Ulcers

Venous Leg Ulcers

Chronic

Wound

Epiceram is a non-sterile, viscous, lipid-rich emulsion

Epiceram Skin Barrier Function

A skin protectant used for temporarily protecting minor cuts, scraps, burns, and helps to protect and help relieve chapped or cracked skin and lips.

Vaseline Petroleum Jelly

Topical serum designed to fortify delicate skin with essential lipids. The proprietary blend of naturally occurring lipids contained in Ceramiseal are designed to improve the barrier function of your skin's outer layer; thereby restoring critical moisture balance and improving physical appearance and function.

Ceramiseal

IU Health Methodist Hospital

Wound Healing Endpoint and Recurrence

If a history of wound biofilm infection results in elevated TEWL at wound sites that appear closed, defectively closed wounds featuring high TEWL show higher "recurrence rate" than functionally closed wounds with low TEWL. This will be identified by how many subjects with a high TEWL reading and biofilm infection, have recurrence of their wound versus subjects with a low TEWL reading.

If topical application of the Ceramiseal™ or the FDA approved EpiCeram® restores barrier function to defectively closed wounds. These will be compared to a Placebo cream, Vaseline and will be seen after 3 months of application to the wound site.

ceramide/кръвоизлив

Effects of Fenofibrate Therapy in Diabetic Nephropathy

Wound Healing Endpoint and Recurrence

Най-пълната база данни за лечебни билки, подкрепена от науката